K2 Principal Fund L.P. bought a new stake in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,000 shares of the company's stock, valued at approximately $359,000. K2 Principal Fund L.P. owned approximately 0.05% of USANA Health Sciences as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. R Squared Ltd bought a new stake in USANA Health Sciences during the 4th quarter valued at $28,000. Exchange Traded Concepts LLC raised its position in USANA Health Sciences by 11.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,578 shares of the company's stock valued at $308,000 after purchasing an additional 869 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in USANA Health Sciences by 15.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,234 shares of the company's stock valued at $260,000 after purchasing an additional 985 shares in the last quarter. Franklin Resources Inc. raised its position in USANA Health Sciences by 4.8% during the 4th quarter. Franklin Resources Inc. now owns 22,070 shares of the company's stock valued at $792,000 after purchasing an additional 1,020 shares in the last quarter. Finally, Principal Financial Group Inc. raised its position in USANA Health Sciences by 2.8% during the 4th quarter. Principal Financial Group Inc. now owns 53,603 shares of the company's stock valued at $1,924,000 after purchasing an additional 1,480 shares in the last quarter. 54.25% of the stock is owned by institutional investors.
USANA Health Sciences Trading Down 1.8%
Shares of USNA traded down $0.54 during trading hours on Wednesday, hitting $29.20. The company had a trading volume of 252,018 shares, compared to its average volume of 130,124. The company has a market capitalization of $543.79 million, a PE ratio of 10.32, a price-to-earnings-growth ratio of 0.93 and a beta of 0.60. USANA Health Sciences, Inc. has a one year low of $23.10 and a one year high of $49.78. The company's fifty day moving average price is $27.20 and its two-hundred day moving average price is $32.56.
USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.70 by $0.03. The firm had revenue of $249.54 million during the quarter, compared to analyst estimates of $243.08 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. During the same period in the previous year, the company posted $0.86 EPS. Analysts forecast that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.
Analyst Ratings Changes
A number of equities research analysts have weighed in on USNA shares. DA Davidson decreased their target price on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, February 27th. StockNews.com downgraded USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Finally, Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th.
Get Our Latest Analysis on USNA
Insider Buying and Selling
In related news, CFO G Doug Iiekking sold 4,548 shares of the business's stock in a transaction on Friday, May 9th. The stock was sold at an average price of $29.61, for a total transaction of $134,666.28. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jim Brown sold 5,000 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $29.47, for a total value of $147,350.00. Following the transaction, the chief executive officer now owns 15,716 shares in the company, valued at approximately $463,150.52. This trade represents a 24.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,142 shares of company stock worth $655,050 in the last ninety days. 0.63% of the stock is owned by insiders.
USANA Health Sciences Profile
(
Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Read More
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
